Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Substance Withdrawal Clear all
Terminated Phase 4 Interventional Results available

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

NCT01362205
View directory record Official record
Conditions
Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
Interventions
Dexmedetomidine, Placebos
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 89 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Not listed Phase 2 Interventional

Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder

NCT04850664
View directory record Official record
Conditions
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms, Craving, Negative Affectivity
Interventions
CBOT + TAU, Sham + TAU
Drug
Lead sponsor
Evon Medics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Not applicable Interventional Results available

tAN to Mitigate Withdrawal Behaviors in Neonates

NCT04588519
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
33 Weeks to 1 Year
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging

NCT01664741
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Nicotine patch - transdermal, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 60 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Improving Buprenorphine Detoxification Outcomes With Isradipine

NCT01895270
View directory record Official record
Conditions
Opioid Dependence
Interventions
Isradipine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Recruiting Not applicable Interventional

Non-invasive Vagal Nerve Stimulation as Novel Treatment to Improve Functional Outcomes in Veterans With Alcohol Use Disorder

NCT06399653
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Cervical transcutaneous vagus nerve stimulation (active comparator), Cervical transcutaneous vagus nerve stimulation (sham comparator)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal

NCT01863186
View directory record Official record
Conditions
Opioid Dependence, Acute Opioid Withdrawal Syndrome
Interventions
Lofexidine HCl, Placebo, Open Label Lofexidine HCL
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Clovis, California • Escondido, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Not applicable Interventional Results available

Nicotine Withdrawal Symptoms and Smoking Relapse

NCT01511614
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Transcranial Direct Current Stimulation, sham, Nicotine patch, Placebo patch, Varenicline Pill, Placebo pill, Motivational Interviewing
Device · Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal

NCT00664404
View directory record Official record
Conditions
Smoking
Interventions
Functional Magnetic Resonance Imaging (fMRI)
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

NCT00637000
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Buprenorphine soluble film, Buprenorphine/naloxone film strip, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 4 Interventional Results available

Nicotine Patch for Marijuana Withdrawal

NCT01400243
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Nicotine, Placebo Patch
Drug
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 50 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Gabapentin for Abstinence Initiation in Alcohol Dependence

NCT01141049
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Recruiting Phase 1 Interventional

Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder

NCT06538558
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Tezampanel, Placebo
Drug
Lead sponsor
Proniras Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Ibudilast and Withdrawal-Related Dysphoria

NCT03489850
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ibudilast, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 3 Interventional

Lofexidine for Opiate Withdrawal - 1

NCT00032942
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Lofexidine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 4 Interventional

Long-Term Lamivudine Therapy for Chronic Hepatitis B

NCT00120354
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

Tramadol to Reduce Opioid Withdrawal Symptoms

NCT00142896
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Tramadol, Naloxone, Morphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Family Based Prevention of Alcohol and Risky Sex for Older Teens

NCT03521115
View directory record Official record
Conditions
Alcohol Drinking, Alcohol Intoxication, Alcohol Poison, Alcohol-Related Disorders, Alcohol Impairment, Alcohol Withdrawal, Alcohol Abstinence, Alcohol; Harmful Use, Sex Behavior, Sexual Aggression, Sexual Harassment, Relation, Interpersonal
Interventions
Smart Choices 4 Teens
Behavioral
Lead sponsor
Pacific Institute for Research and Evaluation
Other
Eligibility
16 Years to 17 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 20, 2026, 6:16 PM EDT
Withdrawn Phase 4 Interventional

Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal

NCT00781755
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
varenicline, Adaptation of Motivational Interviewing
Drug · Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Brockton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 20, 2026, 6:16 PM EDT
Recruiting Phase 3 Interventional

Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

NCT05834478
View directory record Official record
Conditions
Withdrawal Symptoms, Opioid Use Disorder, Opioid Use
Interventions
Transcutaneous Cervical Vagal Nerve Stimulation, Sham Stimulation, [F-18]Fallypride
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

Activity Monitoring Assessment of Opiate Withdrawal - 4

NCT00000335
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Morphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1996
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Not applicable Interventional

A Study of SPG Block for Opioid Withdrawal

NCT04946656
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
sphenopalatine ganglion block
Procedure
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
22 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Not applicable Interventional

Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes

NCT01681875
View directory record Official record
Conditions
Tobacco Dependence
Interventions
very low nicotine content cigarettes
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
9
States / cities
San Francisco, California • Tampa, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 20, 2026, 6:16 PM EDT
Recruiting Phase 1 Interventional

Effects of Cannabidiol on Stress and Nicotine Withdrawal

NCT07001930
View directory record Official record
Conditions
CBD, Stress, Nicotine Dependence, Tobacco Smoking
Interventions
Epidiolex
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 20, 2026, 6:16 PM EDT